Nefrologia xx (2025) 501345







Review

Safety and efficacy of sodium-glucose co-transporter-2 inhibitors and aldosterone inhibitors combinations in chronic kidney disease: A systematic review and meta-analysis

Seguridad y eficacia de las combinaciones de inhibidores del cotransportador sodio-glucosa-2 e inhibidores de la aldosterona en la enfermedad renal crónica: una revisión sistemática y un metanálisis

Ahmed W. Hageen ^{a,b}, Reem Sayad ^{a,c,1,*}, Alyaa Khaled Abdelmonem ^{a,d}, Katia Latifa ^{a,e}, Lina Musallam ^{a,f}, Moustafa Abouelkheir ^{a,g}, Sherif Mira ^{a,g}, Ahmed Awad ^{a,g}, Ahmed Afsa ^{a,g}, Waleed Nassar ^{a,g}, Gehad El Ashal^a, Mohamed Elmasry^{a,h}, Eshak I. Bahbah ^{a,i}

^a General Medicine Research Group, MedDots Academy, Cairo, Egypt

^b Faculty of Medicine, Tanta University, Tanta, Egypt

^c Faculty of Medicine, Assiut University, Assiut, Egypt

^d Faculty of Medicine, Aswan University, Aswan, Egypt

^e Faculty of Medicine, Damascus University, Damascus, Syria

^f PharmD, BCPS, University of Jordan, Jordan

⁸ Emergency Medicine Department, Pilgrim Hospital, United Lincolnshire NHS Trust, Lincolnshire, United Kingdom

^h Faculty of Medicine, Alexandria University, Alexandria, Egypt

ⁱ Faculty of Medicine, Al-Azhar University, Damietta, Egypt

$A\ R\ T\ I\ C\ L\ E\ \ I\ N\ F\ O$

Keywords: Chronic kidney disease Sodium-glucose co-transporter-2 inhibitors Non-steroidal mineralocorticoid receptor antagonists Type 2 diabetes Mineralocorticoid receptor antagonists Aldosterone inhibitors Aldosterone synthase inhibitors

ABSTRACT

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and aldosterone inhibitors show promise for treating chronic kidney disease (CKD). This systematic review and meta-analysis explored the efficacy and safety of aldosterone inhibitors plus SGLT2i combination compared to their effects. We searched PubMed, Scopus, Web of Science, Cochrane Central Register of Controlled Trials [CENTRAL], and EBSCOhost. We reported dichotomous outcomes as pooled relative ratios and continuous outcomes as standardized mean differences with a 95% confidence interval. Three studies were included in this meta-analysis. The combination therapy was associated with a significantly higher rate of 30% reduction of urine albumin creatinine ratio (UACR) compared to SGLT2i (RR = 2.38, 95% CI, 1.46–3.46, P < 0.001; $I^2 = 0\%$, P = 0.54) and compared to MRA $(RR = 1.34, 95\% \text{ CI}, 1.12-1.60, P = 0.001; I^2 = 13\%, P = 0.28)$. It also showed a significant reduction in the UACR compared to SGLT2i (SMD = -1.47, 95% CI, -2.25 to $-0.68, P = 0.0003; I^2 = 78\%, P = 0.03$) but no significant reduction compared to aldosterone inhibitors (SMD = -0.10, 95% CI, -0.38 to 0.19, P = 0.51; $I^2 = 67\%$, P = 0.05). The pooled data showed no significant difference in the incidence of serious adverse events between the combination therapy and SGLT2i (RR = 1.01, 95% CI, 0.72–1.41, P = 0.96; $I^2 = 0\%$, P = 0.58) or MRA (RR = 1.01, 95% CI, 0.79–1.30, P = 0.92; $I^2 = 0\%$, P = 0.90). In conclusion, combining SGLT2i and aldosterone inhibitors may offer a promising approach for managing albuminuria and potentially slowing kidney disease progression in CKD patients.

We registered the protocol in PROSPERO CRD42024511675.

* Corresponding author.

https://doi.org/10.1016/j.nefro.2025.501345

Received 20 October 2024; Accepted 26 April 2025

Available online xxx

0211-6995/© 2025 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article in press as: A.W. Hageen, R. Sayad, A. Khaled Abdelmonem, et al., Safety and efficacy of sodium-glucose co-transporter-2 inhibitors and aldosterone inhibitors combinations in chronic kidney disease: A systematic review and meta-analysis, Nefrologia, https://doi.org/10.1016/j.nefro.2025.501345

E-mail address: reem.17289806@med.aun.edu.eg (R. Sayad).

¹ Co-first author.

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

Palabras clave:

Enfermedad renal crónica Inhibidores del cotransportador sodio-glucosa 2 Antagonistas del receptor de mineralocorticoides no esteroides Diabetes tipo 2 Antagonistas del receptor de mineralocorticoides Inhibidores de la aldosterona Inhibidores de la aldosterona sintasa

ARTICLE IN PRESS

Nefrologia xx (2025) 501345

RESUMEN

Los inhibidores del cotransportador de sodio-glucosa tipo 2 (iSGLT2) y los inhibidores de la aldosterona muestran resultados prometedores en el tratamiento de la enfermedad renal crónica (ERC). Esta revisión sistemática y metanálisis exploró la eficacia y la seguridad de la combinación de inhibidores de la aldosterona e iSGLT2 en comparación con sus efectos. Se realizaron búsquedas en PubMed, Scopus, Web of Science, el Registro Cochrane Central de Ensayos Controlados [CENTRAL] y EBSCOhost. Los resultados dicotómicos se presentaron como razones relativas agrupadas y los resultados continuos como diferencias de medias estandarizadas con un intervalo de confianza del 95%. Se incluyeron tres estudios en este metanálisis. La terapia combinada se asoció con una tasa significativamente mayor de reducción del 30% del cociente albúmina-creatinina en orina (UACR) en comparación con SGLT2i (RR = 2,38, IC del 95%, 1,46: 3,46, P < 0,001; I2 = 0%, P = 0,54) y en comparación con MRA (RR = 1,34, IC del 95%, 1,12: 1,60, P = 0,001; I2 = 0,001; I 13%, P = 0,28). También mostró una reducción significativa en el UACR en comparación con SGLT2i (SMD = -1,47, IC 95%, -2,25: -0,68, P = 0,0003; I2 = 78%, P = 0,03) pero ninguna reducción significativa en comparación con los inhibidores de la aldosterona (SMD = -0,10, IC 95%, 0,38: 0,19, P = 0,51; I2 = 67%, P=0,05). Los datos agrupados no mostraron diferencias significativas en la incidencia de eventos adversos graves entre la terapia combinada y los inhibidores del SGLT2 (RR = 1,01; IC del 95%, 0,72-1,41; p = 0.96; I^2 = 0%, p = 0.58) o la ARM (RR = 1.01; IC del 95%, 0.79-1.30; p = 0.92; I² = 0%, p = 0.90). En conclusión, la combinación de inhibidores del SGLT2 e inhibidores de la aldosterona podría ofrecer un enfoque prometedor para el manejo de la albuminuria y, potencialmente, ralentizar la progresión de la enfermedad renal en pacientes con ERC.

Introduction

Chronic kidney disease (CKD) is defined as decreased kidney function (GFR $< 60 \text{ mL/min per } 1.73 \text{ m}^2$), or by markers of kidney damage, or both, for at least 3 months. While many conditions can lead to CKD, hypertension, and diabetes are the main causes globally.^{1,2} Around 800 million individuals globally have CKD.³ The prevalence of CKD is steadily rising over time, now affecting about 10% of people worldwide. There is an increase in the prevalence of CKD which makes it a major public health issue that requires attention.⁴ The first-line medications for treating individuals with CKD are angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). It has been demonstrated that the use of ACEI or ARBs has a greater impact on reducing proteinuria and delaying the course of renal disease than placebo treatment. The effectiveness of ARB and ACEI is comparable.⁵ In recent years, several clinical trials have demonstrated the effectiveness of various medications for kidney protection. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are among these drugs.⁶

SGLT2i were initially proposed as glucose-lowering and weightlowering drugs in patients with type 2 diabetes mellitus (DM).^{10,11} SGLT2i reduces the reabsorption of filtered glucose from the tubular lumen, decreases the renal threshold for glucose (RTG), and promotes urinary glucose excretion by inhibiting the activity of SGLT2 proteins that are located in the proximal convoluted tubules of the kidneys.^{12–14} However, recent cardio-renal trials have demonstrated that the benefits of SGLT2i go beyond managing type 2 DM. These medications are effective in preventing cardiovascular events and slowing the progression of CKD.^{14,15} One of these trials is the DAPA-CKD trial, which concluded that compared to a placebo, dapagliflozin significantly reduces the risk of a composite outcome in patients with CKD, regardless of DM status. This includes a persistent reduction in estimated glomerular filtration rate (eGFR) of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.⁷

Aldosterone expedites the progression of chronic renal disease.^{16,17} Aldosterone exerts harmful effects through many mechanisms, including inflammation and fibrosis, which culminate in glomerular, tubulointerstitial, and vascular damage to the kidney.¹⁸ The recent discovery of aldosterone inhibitors such as non-steroidal mineralocorticoid receptor antagonists (MRAs) represents a significant advancement in cardio-renal disease treatment.^{8,9} Similar to steroidal MRAs, non-steroidal MRAs have positive effects on inflammation, remodeling, and fibrosis in the kidneys, heart, and vasculature.

However, non-steroidal MRAs distribute equally between the kidneys and heart, showing better suppression of mineralocorticoid receptor (MR) co-regulator recruitment and fibrosis than steroidal MRAs.^{19,20} Recent trials, including FIGARO-DKD and FIDELIO-DKD, disclosed that finerenone reduced the risk of cardiovascular and major kidney events in patients with type 2 DM and CKD.^{9,21} Additionally, aldosterone synthase inhibitors directly reduce aldosterone synthesis, potentially increasing treatment efficacy.^{18,22}

We designed this systematic review and meta-analysis to study the safety and efficacy of SGLT2i and aldosterone inhibitors either MRAs or aldosterone synthase inhibitors combination in CKD. Additionally, we aimed to check whether this dual therapy is superior to either agent alone.

Methods

Study protocol and registration

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), we carried out this systematic review and meta-analysis of randomized clinical trials.²³ We followed the instructions provided in Cochrane's Handbook of Systematic Reviews of Interventions for every step we took.²⁴ We registered the protocol in PROSPERO CRD42024511675.

Search strategy and data collection

We searched four electronic databases: PubMed, Scopus, Web of Science, Cochrane Central Register of Controlled Trials [CENTRAL], and EBSCOhost. We searched for all studies published until January 2024. Details of the search strategy are mentioned in Table S1.

We assessed all retrieved studies for our eligibility criteria in two steps: title and abstract screening, then full-text screening. Studies that met our eligibility criteria are included. We manually screened the references to the previous reviews and our included studies. Two separate authors did all the screening steps, and a third author resolved all conflicts.

Eligibility criteria

We included randomized controlled trials (RCTs) and observational studies, including retrospective and prospective studies

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

reported in English that fulfilled the illustrated PICO criteria as follows: P: Patients suffering from CKD either diabetic or non-diabetic. I: SGLT2i plus aldosterone inhibitors "MRAs or aldosterone synthase antagonist" combinations. C: SGLT2 inhibitor monotherapy, aldosterone inhibitors either MRAs or aldosterone synthase inhibitors monotherapy, conventional therapeutic methods, or placebo. O: Any of the following:

- The incidence of a 30% reduction of urine albumin-to-creatinine ratio (UACR)
- The incidence of a 50% reduction of UACR
- Changes in UACR
- Changes in blood pressure
- Changes in eGFR
- Changes in measured glomerular filtration rate (mGFR)
- Serious adverse events
- Any adverse events
- The incidence of hyperkalemia
- The incidence of patients having potassium more than 5 mmol

Data extraction and outcome measurement

Two authors extracted data using Excel in three sheets: 1 - summary of the included trials' settings; 2 - baseline characteristics of the participants in the included trials; 3 - data of the reported outcomes, then any conflict between both authors was resolved by a third author.

Quality assessment

We assessed the methodology of the included studies using the Cochrane Risk of Bias Assessment Tool (ROB-II).²⁵ We also used the ROB-II tool for crossover studies.²⁶ The authors rated each domain as low, high risk, or unclear. We used Risk-of-bias Visualization (Robvis) software to visualize ROB figures.²⁷

Data analysis

We used the Review Manager software (RevMan 5.4). Continuous outcomes were analyzed by mean difference (MD), standardized mean difference (SMD), and 95% confidence interval (CI) throughout the entire record.

Dichotomous data were analyzed as risk ratio (RR) and 95% CI. Statistical heterogeneity among the studies was assessed by visual inspection of the forest plot, besides using *I*-squared (I^2) and chi-squared (Chi²) statistics. I^2 values of 50% were indicative of significant heterogeneity. Subgroups or subsets will be applied for the outcomes eligible for that.

Results

Study selection

A literature search through PubMed, Scopus, Web of Science, Cochrane CENTRAL, EBSCOhost, and the manual search has revealed 4066 articles with 2383 duplicates. Title and abstract screening were done on 1683 articles, and 1252 were excluded. Full-text screening was performed on 39 studies. Finally, three studies were included in this systematic review and meta-analysis. The study flow diagram is shown in Fig. 1.

Study characteristics

This systematic review and meta-analysis includes three randomized clinical trials (RCTs).^{28–30} One of them was conducted in three clinical trial centers in Italy and Spain,²⁹ and the other two studies were conducted in multiple centers across various countries.^{28,30} There is a randomized controlled crossover trial that included 46 patients in the trial. Patients have been treated with eplerenone 50 mg once daily, dapagliflozin 10 mg once daily, or a combination of eplerenone 50 mg once daily and dapagliflozin 10 mg once daily in random order during three consecutive open-label crossover treatment periods of four weeks each, with four-week washout periods in between each active treatment period.^{23,29} The second study examined three dosages of BI 690517, with or without the SGLT2i empagliflozin, combined with ACE inhibitors or ARB.²⁸ The last one included 5674 participants who were divided into two groups. Of them, 259 patients were on an SGLT2i at baseline. These patients were divided into two groups: 135 and 124 in the intervention and control groups respectively. The remaining participants, 5415 patients, did not receive SGLT2i at baseline. These patients were divided into two groups: 2709 and 2706 in the intervention and control groups respectively.³⁰ The mean age of the included patients ranged from 61.8 to 65.8. Most of the included studies in the intervention and control group are males (69.9%), and white ethnicity (63.09%). The summary and baseline characteristics of the included studies are shown in Tables 1 and 2, and Table S2.

The follow-up duration in the study by Provenzano et al. was short, consisting of three 4-week treatment periods (dapagliflozin, eplerenone, and their combination), each separated by 4-week washout periods, for a total duration of approximately 12 weeks.²⁹ This design allowed for the assessment of immediate effects on albuminuria and GFR following treatment initiation. Similarly, the study by Tuttle et al. had a short follow-up period comprising an 8-week run-in, a 14-week treatment phase, and a 4-week post-treatment follow-up, totaling around 18 weeks.³¹ This study focused on short-term changes in UACR, eGFR, and serum potassium levels. In contrast, the study by Rossing et al. featured a long-term follow-up with a median duration of 2.6 years, enabling a comprehensive evaluation of finerenone's sustained effects on GFR decline, kidney failure, and cardiovascular outcomes.³⁰ Among the three included studies, only the FIDELIO-DKD trial provides long-term data, whereas ROTATE-3 and BI 690517 offer insights into early, short-term changes. This distinction has been emphasized in the revised manuscript to more accurately contextualize the findings related to GFR changes.

Quality assessment

All included studies showed an overall low risk of bias. One study was assessed by the ROB-II tool for crossover studies,²⁴ and the other two studies were assessed by the ROB-II tool (Fig. 2a and b).

Primary outcomes

Incidence of reduction in urine albumin creatinine ratio (UACR)

Two studies reported the effect of SGLT2i combined with aldosterone inhibitors on the incidence of a 30% reduction in UACR compared to SGLT2i alone. The pooled data demonstrated a significant difference favoring the combination therapy (RR = 2.38, 95% CI, 1.64–3.46, P < 0.00001; $I^2 = 0\%$, P = 0.54; Fig. 3a). Similarly, when compared to MRAs alone, the combination therapy also showed a significant advantage (RR = 1.34, 95% CI, 1.12–1.60, P = 0.001; $I^2 = 13\%$, P = 0.28; Fig. 3b). Additionally, for a 50% reduction in UACR, the combination therapy was favored over SGLT2i (RR = 2.60, 95% CI, 1.72–3.93, P < 0.00001; $I^2 = 0\%$,

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.



Fig. 1. PRISMA flowchart of the included studies.

P = 0.75; Fig. 3c) and MRAs (RR = 1.34, 95% CI, 1.11-1.61, P = 0.002; $I^2 = 16\%$, P = 0.28; Fig. 3d).

Change of urine albumin creatinine ratio (UACR)

Two studies reported that the combination of SGLT2i and aldosterone inhibitors resulted in a significant reduction in UACR when compared to SGLT2i alone (SMD = -1.47, 95% CI, -2.25 to -0.68, P = 0.0003; $I^2 = 78\%$, P = 0.03; Fig. 4a). However, when compared to aldosterone inhibitors, the pooled data from three studies did not show a significant reduction in UACR (SMD = -0.10, 95% CI, -0.38 to 0.19, P = 0.51; $I^2 = 67\%$, P = 0.05; Fig. 4b).

Change of estimated glomerular filtration rate (eGFR)

Two studies indicated that the combination therapy resulted in a significant reduction in eGFR compared to SGLT2i alone (MD = -1.94, 95% CI, -3.24 to -0.63, P = 0.004; $I^2 = 25\%$, P = 0.25; Fig. 5a). Conversely, when compared to MRAs, the combination therapy did not result in a significant reduction in eGFR (MD = 0.26, 95% CI, -0.06 to -0.57, P = 0.12; $I^2 = 0\%$, P = 0.35; Fig. 5b).

Secondary outcomes

Change of systolic blood pressure (SBP)

Three studies reported that the combination therapy significantly reduced SBP compared to SGLT2i (MD = -8.86, 95% CI, -12.79 to -4.93, P < 0.00001; $I^2 = 59\%$, P = 0.12; Fig. 6a) and compared to aldosterone inhibitors (MD = -3.00, 95% CI, -5.50 to -0.50, P = 0.02; $I^2 = 96\%$, P < 0.00001; Fig. 6b).

Safety profile

Three studies reported the incidence of serious AEs associated with combination therapy compared to SGLT2i and aldosterone inhibitors. The pooled data showed no significant difference in the incidence of serious AEs between the combination therapy and SGLT2i (RR = 1.01, 95% CI, 0.72–1.41, P = 0.96; $I^2 = 0\%$, P = 0.58) or aldosterone inhibitors (RR = 1.01, 95% CI, 0.79–1.30, P = 0.92; $I^2 = 0\%$, P = 0.90; Fig. 7a).

Three studies also reported the incidence of any AEs associated with the combination therapy compared to SGLT2i and aldosterone inhibitors. The pooled data showed no significant difference in the A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

ARTICLE IN PRESS

Table 1 Summary of the	included studies.									
Study ID	Study arm	Sample size	Study design	Country/ region	Combined medications used	Treatment dose	Frequency	Treatment duration	Follow-up duration	Main outcome
Provenzano et al., 2022	Dapagliflozin Eplerenone Dapagliflozin + eplerenone	46	Prospective, randomized, open-label crossover trial	Italy and Spain (3 sites)	Eplerenone 50 mg OD, dapagliflozin 10 mg OD, or combination	Dapagliflozin 10 mg; eplerenone 50 mg	Once daily	Three 4-week treatment periods with 4-week washouts	Until end of study	Correlation between 24-h UACR changes from baseline with dapagliflozin, eplerenone, and combination
Rossing et al., 2022	Finerenone + SGLT2i Placebo (with SGLT2i) Finerenone + no SGLT2i Placebo (no SGLT2i)	124 135 2709 2706	RCT	48 countries	ACEi, ARB, β-blocker, diuretics, statins, potassium-lowering agents, glucose- agents, glucose- lowering agents, insulin, GLP-1RA, SGLT2i	Not specified	Not specified	N/A	N/A	Positive outcomes with finerenone in CKD and T2D, regardless of SGLT2i use
Tuttle et al., 2024	 BI 690517 placebo + empagliflozin BI 690517 3 mg + empagliflozin BI 690517 10 mg + empagliflozin BI 690517 20 mg + empagliflozin BI 690517 placebo BI 690517 10 mg + placebo BI 690517 10 mg + placebo BI 690517 20 mg + placebo 	74 74 72 72 72 72	RCT	Multinational (27 countries)	ARB, ACEi, GLP-1RA; background empagliflozin or placebo	BI 690517: 3 mg, 10 mg, 20 mg 3 mg 10 mg 20 mg - 3 mg 20 mg 20 mg	N/A	14 weeks	Follow-up at week 18 (4 weeks after washout)	Reduction in UACR and eGFR, especially with BI 690517 + empagliflozin
Abbreviations: UA receptor agonist; 6	CR: urine albumin to creatinine ratio; SC 9GFR: estimated glomerular filtration rat	3LT2i: sodiui te; BI 690517	n-glucose transpoi 7: potent, highly se	rt protein 2 (SGLT: lective aldosteron	 2) inhibitor; ACEi: angiote e synthase inhibitor; CKD: 	nsin convertase er chronic kidney di	rzyme inhibitor; Al sease; T2D: type 2	RB: angiotensin re diabetes mellitus;	ceptor blocker; Gl OD: once daily; R	LP-1RA: glucagon-like peptide-1 CT: randomized controlled trial.

Seen, n. ouyu	1. 12; 13 1. 38 1. 38	cker: 	cker: 1: 84; K ⁺ -	, <u>;;</u> ,		IRA:	1RA:	1RA:	IRA:	1RA:	1RA:	IRA:	1RA:
Co-interventions	ACEi: 17; ARB: 29, β-bloc 17; CCB: 24; thiazide: 1 loop: 11; insulin: 11; statir	ACEi: 36; ARB: 88; β-bloc 64; metformin: 89; insulin statin: 102; GLP-1RA: 17;	ACEI: 41; ARB: 94; §-bloc ACEI: 41; ARB: 94; §-bloc 73; metformin: 93; insulin statin: 121; GLP-1RA: 3; homeirar 1	ACE:: 914, ARB: 1791; β- ACE:: 914, ARB: 1791; β- blocker: 1398; metformin 1162; insulin: 1754; stati 2003; GLP-1RA: 172; K ⁺ Louosicor 66	Lowerung, or ACE:: 951; ARB: 1752; β- ACE:: 951; ARB: 1752; β- blocker: 1433; metformin 1146; insulin: 1710; stati 1989; GLP-1RA: 174; K ⁺ - lowering: 65	ACEi: 24; ARB: 49; GLP-1 5	ACEi: 23; ARB: 55; GLP-1 10	ACEi: 18; ARB: 55; GLP-1 6	ACEi: 24; ARB: 49; GLP-1 11	ACEi: 25; ARB: 49; GLP-1 7	ACEi: 29; ARB: 41; GLP-1 4	ACEi: 14; ARB: 56; GLP-1 4	ACEi: 21; ARB: 51; GLP-1 3
UACR mg/g, mean (SD)	401 (101)	772 (671.3)	737 (663.2)	978 (883.4)	1005 (895.2)	492.7 (632.1)	576.3 (609.8)	467.7 (475.6)	499.7 (446.8)	503.3 (532.4)	602.7 (750.7)	453.7 (427.4)	554.0 (448.6)
eGFR mL/ min/ 1.73 m ² , mean (SD)	58.1 (18.6)	51.8 (11.3)	50.3 (12.5)	44.0 (12.5)	44.0 (12.5)	49.6 (17.5)	50.3 (16.7)	50.2 (17.9)	51.5 (17.1)	54.6 (18.7)	51.8 (16.4)	56.1 (20.9)	51.6 (16.0)
BMI kg/ m ² , mean (SD)	30.8 (6.2)	31.8 (5.8)	31.8 (5.5)	31.1 (6.0)	31.1 (6.0)	29.5 (5.2)	30.3 (5.8)	29.6 (5.3)	29.4 (5.9)	30.4 (6.0)	30.5 (5.0)	30.3 (5.2)	29.5 (5.3)
CRP mg/L, mean (SD)	NA	3.96 (5.21)	3.46 (3.87)	4.57 (9.01)	4.66 (9.32)					N/A			
DBP mmHg, mean (SD)	80 (7.5)	74.9 (10.2)	76.3 (9.2)	75.9 (9.7)	75.8 (9.7)	76.9 (10.7)	76.4 (9.2)	77.1 (9.4)	75.6 (8.6)	80.2 (11.4)	78.5 (9.1)	75.9 (8.7)	77.4 (9.0)
SBP mmHg, mean (SD)	136.3 (9.0)	135.4 (14.4)	134.1 (14.5)	138.2 (14.3)	138.2 (14.4)	132.7 (13.9)	134.4 (16.4)	131.7 (13.1)	131.8 (16.0)	133.9 (15.9)	134.8 (18.7)	135.0 (15.1)	136.1 (16.2)
HbA1c %, mean (SD)	48.9 (1.7)	8.02 (1.15)	7.98 (1.26)	7.65 (1.33)	7.67 (1.36)	7.0 (1.3)	7.1 (1.2)	6.9 (1.4)	7.1 (1.3)	7.0 (1.4)	6.8 (1.2)	6.9 (1.3)	6.9 (1.3)
DM, n (%)	32 (69.6%)	AN	NA	NA	ΥN	51 (68.9%)	67 (88.2%)	46 (62.2%)	54 (73.0%)	49 (67.1%)	48 (67.6%)	52 (72.2%)	47 (65.3%)
Race (n)	White: 45; other: 1	White: 91; Asian: 25; Black: 1	White: 89; Asian: 33; Black: 8	White: 1686; Asian: 692; Black: 139	White: 1726; Asian: 690; Black: 116	Asian: 19; Black: 10;	wnite: 42 Asian: 17; Black: 9;	White: 49 Asian: 27; Black: 6;	White: 35 Asian: 20; Black: 7;	White: 45 Asian: 16; Black: 10;	White: 44 Asian: 23; Black: 3;	White: 42 Asian: 15; Black: 9; White: 45	Asian: 19; Black: 9; White: 40
Male, n (%)	35 (76.1%)	92 (74.2%)	96 (71.1%)	1861 (68.7%)	1934 (71.5%)	43 (58.1%)	49 (64.5%)	44 (59.5%)	54 (73.0%)	55 (75.3%)	51 (71.8%)	49 (68.1%)	45 (62.5%)
Age (Y), mean (SD)	69.5 (7.6) 49.5 (1.7) 50.0 (1.7)	63.9 (9.3)	62.3 (9.9)	65.5 (8.9)	65.8 (9.1)	63.4 (10.3)	65.4 (11.2)	64.4 (12.3)	61.8 (12.2)	62.3 (11.4)	64.4 (11.8)	64.8 (9.9)	64.3 (10.7)
u	46	124	135	2709	2706	74	76	74	74	73	71	72	72
Study arm	Dapagliflozin Eplerenone Dapagliflozin + eplerenone	Finerenone + SGLT2i	Placebo + SGLT2i	Finerenone + no SGLT2i	Placebo + no SGLT2i	BI 690517 placebo +	empaguriozin BI 690517 3 mg +	empagliflozin BI 690517 10mg +	empagliflozin BI 690517 20 mg +	empaglitlozin BI 690517 placebo +	placebo BI 690517 3mg + placebo	BI 690517 10mg + placebo	BI 690517 20mg + placebo
Study ID	Provenzano et al., 2022			Rossing et al., 2022						Tuttle et al., 2024			

PRESS

6

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

Nefrologia xx (2025) 501345

(a)	_				Risk of bias			
		D1	D2	D3	D4	D5	D6	Overall
Study	Provenzano et al. 2022	+	+	+	+	+	+	+
		01: Risk of bias a 02: Risk of bias a 03: Risk of bias o 04: Risk of bias o 05: Risk of bias in 06: Bias in select	trising from the ra trising from period lue to deviations lue to missing ou measurement of ion of the reported	andomization proo d and carryover e from the intended tcome data of the outcome ed result	cess Iffects in a cross I interventions (e	over trial ffect of starting an	d adhering to inter	Judgement
(b)				Ris	k of bias o	domains		
		D1	D	2	D3	D4	D5	Overall
dy	Tuttle et al. 2024	• •)		+	+	+	+
StL	Rossing et al. 202	22 +			+	+	+	+
		Domain D1: Bias D2: Bias D3: Bias D4: Bias D5: Bias	s: s arising fron s due to devi s due to miss s in measure s in selection	n the random ations from in sing outcome ment of the o of the repor	ization procentended intended intende	ess. rvention.		Judgement

Fig. 2. Risk of Bias-II (ROB-II) of the included studies. (a) ROB-II of RCT. (b) ROB-II of crossover clinical trial.

(2)											
(a) Studies Subaroum	Experimen	ntal Tetel Ev	Control	l Mais	R NU	isk Ratio		Ris	k Ratio		
Study of Subgroup	Events	TOTAL EV	ents Tota		Int M-H,	Fixed, 95% CI		MI-H, FD	cea, 95% CI		
Provenzano et al. 2022	16	22	8 2	2 27.5	1% 2. 	00 [1.09, 3.68]					
Rossing et al. 2022	99	140	14 5	U 72.1	1% 2.	23 [1.60, 3.99]					
Total (95% CI)		162	7	2 100.	0% 2.3	38 [1.64, 3.46]			•		
Total events	115		22								
Heterogeneity: Chi ² = 0.3	8, df = 1 (P =	: 0.54); l²:	= 0%			L L	0.01	01	-	10	100
Test for overall effect Z =	4.55 (P < 0.	00001)						0.1			100
(b)	Experin	nental	Contro	ol		Risk Ratio		SGLT-2 Inhibitors	co Risk Ratio	mbination	
Study or Subaroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95	% CI	M-H	. Fixed. 95% (
Provenzano et al. 2022	16	22	g	22	10.8%	1 78 11 01 3	3 1 21				
Rossing et al. 2022	99	140	72	131	89.2%	1 29 [1 07 1	1.551				
recooning of all roll		140	12	101	00.270	1.20 [1.01] 1	1.001				
Total (95% CI)		162		153	100.0%	1.34 [1.12, 1	.60]		٠		
Total events	115		81								
Heterogeneity: Chi ² = 1	.15, df = 1 ((P = 0.28)); I ^z = 13%							10	100
Test for overall effect: Z	= 3.21 (P =	: 0.001)						0.01 0.1		TU	100
								MRAs	ca	moination	
(c)	Experimer	ntal	Control		R	isk Ratio		Ris	k Ratio		
Study or Subgroup	Events	Total Ev	ents Tota	Weid	iht M-H.	Fixed, 95% CI		M-H, Fiz	ced. 95% Cl		
Provenzano et al. 2022	12	22	4 2	2 16.2	2% 3.	00 [1.14, 7.87]				_	
Rossing et al. 2022	99	140	14 5	0 83.8	3% 2.	53 [1.60, 3.99]					
Total (95% CI)		162	7.	2 100.	0% 2.0	60 [1.72, 3.93]			•		
Total events	111		18								
Heterogeneity: Chi ² = 0.1	0, df = 1 (P =	= 0.75); I² =	= 0%				0.01	0.1	1	10	100
Test for overall effect Z =	4.54 (P < 0.	00001)				-		SGLT-2 inhibitors	s	combina	ation
(d)	Experin	nental	Contro	ol		Risk Ratio		1	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95	% CI	M-H	, Fixed, 95% (
Provenzano et al. 2022	12	22	6	22	7.5%	2.00 [0.92, 4	4.371				
Rossing et al. 2022	99	140	72	131	92.5%	1.29 [1.07. 1	1.55]				
-											
Total (95% CI)		162		153	100.0%	1.34 [1.11, 1	.61]		•		
Total events	111		78								
Heterogeneity: Chi ² = 1	.19, df = 1 ((P = 0.28)); I² = 16%							10	100
Test for overall effect: Z	:= 3.10 (P =	: 0.002)						0.01 0.1	PAs	10	mhinatic

Fig. 3. (a) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 30% reduction in urine albumin creatinine ratio compared to SGLT2. (b) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 30% reduction in urine albumin creatinine ratio compared to MRAs. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to SGLT2. (d) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to SGLT2. (d) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to MRAs. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to MRAs. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to MRAs. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to MRAs. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of 50% reduction in urine albumin creatinine ratio compared to MRAs.

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

Nefrologia xx (2025) 501345



Fig. 4. Change of urine albumin creatinine ratio. (a) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on change of urine albumin creatinine ratio compared to SGLT2 i. (b) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on change of urine albumin creatinine ratio compared to aldosterone inhibitors. CI: Confidence Interval; IV: Inverse Variance (method); I²: I-squared statistic (measuring heterogeneity).



Fig. 5. Change of estimated glomerular filtration rate. (a) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on change of estimated glomerular filtration rate compared to SGLT2. (b) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on change of estimated glomerular filtration rate compared to MRAs. CI: Confidence Interval; IV: Inverse Variance (method); I²: I-squared statistic (measuring heterogeneity).

(a)	Combin	nation		SGLT-2	. Inhibit	tors		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Provenzano et al.2022	-10	8.97	22	-4.1	8.97	22	31.4%	-5.90 [-11.20, -0.60]	_
Rossing et al.2022	-7.75	3.86	141	2.47	3.63	50	68.6%	-10.22 [-11.41, -9.03]	■
Tuttle et al.2024	-2.12	0.795	124	-0.94	0.66	2709	0.0%	-1.18 [-1.32, -1.04]	
Total (95% CI)			163			72	100.0%	-8.86 [-12.79, -4.93]	◆
Heterogeneity: Tau ² = 5.4	49; Chi ≇÷	= 2.43,	df = 1 (l	P = 0.12); l ² = {	59%			
Test for overall effect: Z =	= 4.42 (P	< 0.000	001)						-20 -10 0 10 20 Combination SGLT-2 Inhibitors
(1.)									
(d)	Combin	nation		Aldost	erone l	nhibitor	•	Mean Difference	Mean Difference
(D) _ Study or Subgroup	Combin Mean	nation SD	Total	Aldost Mean	erone li SD	nhibitor Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
(D) <u>Study or Subgroup</u> Provenzano et al.2022	Combin Mean -10	stion SD 8.97	Total 22	Aldoste Mean -4.2	erone li SD 9.09	nhibitor: Total 22	Weight 14.6%	Mean Difference IV, Random, 95% CI -5.80 [-11.14, -0.46]	Mean Difference IV, Random, 95% Cl
(D) <u>Study or Subgroup</u> Provenzano et al.2022 Rossing et al.2022	Combin Mean -10 -7.75	SD 8.97 3.86	Total 22 141	Aldost Mean -4.2 -3.83	erone li <u>SD</u> 9.09 2.81	nhibitor Total 22 131	Weight 14.6% 41.8%	Mean Difference IV, Random, 95% Cl -5.80 [-11.14, -0.46] -3.92 [-4.72, -3.12]	Mean Difference IV, Random, 95% Cl
(D) <u>Study or Subgroup</u> Provenzano et al.2022 Rossing et al.2022 Tuttle et al.2024	Combin Mean -10 -7.75 -2.12	SD 8.97 3.86 0.795	Total 22 141 124	Aldost Mean -4.2 -3.83 -0.94	9.09 2.81 0.66	nhibitor: Total 22 131 2709	Weight 14.6% 41.8% 43.6%	Mean Difference IV, Random, 95% Cl -5.80 [-11.14, -0.46] -3.92 [-4.72, -3.12] -1.18 [-1.32, -1.04]	Mean Difference IV, Random, 95% Cl
(D) Study or Subgroup Provenzano et al.2022 Rossing et al.2022 Tuttle et al.2024 Total (95% CI)	Combin Mean -10 -7.75 -2.12	stion <u>SD</u> 8.97 3.86 0.795	Total 22 141 124 287	Aldoste Mean -4.2 -3.83 -0.94	9.09 2.81 0.66	nhibitor Total 22 131 2709 2862	Weight 14.6% 41.8% 43.6% 100.0%	Mean Difference IV, Random, 95% Cl -5.80 [-11.14, -0.46] -3.92 [-4.72, -3.12] -1.18 [-1.32, -1.04] -3.00 [-5.50, -0.50]	Mean Difference IV, Random, 95% Cl
(D) <u>Study or Subgroup</u> Provenzano et al.2022 Rossing et al.2022 Tuttle et al.2024 Total (95% CI) Heterogeneity: Tau ² = 3.	Combin <u>Mean</u> -10 -7.75 -2.12 74: Chi ²	setion <u>SD</u> 8.97 3.86 0.795 = 46.63	Total 22 141 124 287 df = 2	Aldoste Mean -4.2 -3.83 -0.94 (P < 0.0	erone li <u>SD</u> 9.09 2.81 0.66	nhibitor <u>Total</u> 22 131 2709 2862 (1 ² = 96	Weight 14.6% 41.8% 43.6% 100.0%	Mean Difference IV, Random, 95% CI -5.80 [-11.14, -0.46] -3.92 [-4.72, -3.12] -1.18 [-1.32, -1.04] -3.00 [-5.50, -0.50]	Mean Difference IV, Random, 95% CI
(D) <u>Study or Subgroup</u> Provenzano et al.2022 Rossing et al.2022 Tuttle et al.2024 Total (95% CI) Heterogeneity: Tau ² = 3. Test for overall effect. Z =	Combin -10 -7.75 -2.12 74; Chi ² = 2.35 (P	setion <u>SD</u> 8.97 3.86 0.795 = 46.63 = 0.02	Total 22 141 124 287 , df = 2	Aldoste Mean -4.2 -3.83 -0.94 (P < 0.0	erone li <u>SD</u> 9.09 2.81 0.66	Total 22 131 2709 2862 5 ² = 98	Weight 14.6% 41.8% 43.6% 100.0%	Mean Difference IV, Random, 95% CI -5.80 [-11.14, -0.46] -3.92 [-4.72, -3.12] -1.18 [-1.32, -1.04] -3.00 [-5.50, -0.50]	Mean Difference N, Random, 95% CI

Fig. 6. Change of systolic blood pressure. (a) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on the change of systolic blood pressure compared to SGLT2i. (b) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on the change of systolic blood pressure compared to aldosterone inhibitors. CI: Confidence Interval; IV: Inverse Variance (method); I²: I-squared statistic (measuring heterogeneity).

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.





Fig. 7. (a) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of serious adverse events compared to SGLT2i and aldosterone inhibitors. (b) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on the incidence of any adverse events compared to SGLT2i and aldosterone inhibitors. (c) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on incidence of hyperkalemia compared to SGLT2i and aldosterone inhibitors. (d) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on the incidence of hyperkalemia compared to SGLT2i and aldosterone inhibitors. (d) Effect of SGLT2 inhibitors and aldosterone inhibitors combination on the incidence of potassium more than 5 mmol/L compared to SGLT2i and aldosterone inhibitors. CI: Confidence Interval; I²: I-squared statistic (measuring heterogeneity); M-H: Mantel-Haenszel.

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

incidence of any AEs between the combination therapy and SGLT2i (RR = 1.05, 95% CI, 0.97–1.13, P = 0.26; $I^2 = 0\%$, P = 0.92) or aldosterone inhibitors (RR = 0.87, 95% CI, 0.65–1.18, P = 0.38; $I^2 = 92\%$, P < 0.00001; Fig. 7b).

Hyperkalemia

Three studies reported the incidence of hyperkalemia associated with the combination therapy compared to SGLT2i and aldosterone inhibitors. The pooled data showed significant difference in the incidence of hyperkalemia between the combination therapy and SGLT2i (RR = 2.29, 95% CI, 1.15–4.57, P = 0.02; $I^2 = 0\%$, P = 0.78) but associated with no significant difference compared to aldosterone inhibitors (RR = 0.55, 95% CI, 0.27–1.09, P = 0.08; $I^2 = 64\%$, P = 0.06; Fig. 7c).

Two studies reported the incidence of patients who have potassium more than 5 mmol associated with the combination therapy compared to SGLT2i and MRAs. The pooled data showed no significant difference in the incidence of potassium more than 5 mmol between the combination therapy and SGLT2i (RR = 2.67, 95% CI, 0.96–7.41, P = 0.06; $I^2 = 0\%$, P = 0.49) but associated with significant difference compared to MRAs (RR = 0.34, 95% CI, 0.20–0.57, P < 0.00001; $I^2 = 0\%$, P = 0.52; Fig. 7d).

Discussion

This systematic review and meta-analysis included three randomized controlled trials assessing the effect of SGLT2i and aldosterone inhibitors combination versus SGLT2i monotherapy and aldosterone inhibitors either MRAs or aldosterone synthase inhibitors monotherapy in CKD. The mean age range of participants ranged from 61.8 to 65.8 years, majority of participants were male (69.9%) and white ethnicity (63.09%). Pooled analysis showed that the combination therapy (SGLT2i + aldosterone inhibitors) has significant improvements compared to SGLT2i alone or aldosterone inhibitors for both 30% and 50% reductions in UACR. Combination therapy showed a significant reduction of UCAR and eGFR compared to SGLT2i alone, but no significant difference when compared to aldosterone inhibitors alone. There is also a significant reduction with combination therapy compared to both SGLT2I alone and aldosterone inhibitors alone. On the other hand, the combination therapy significantly increased the risk of hyperkalemia compared to SGLT2i alone. The low heterogeneity suggests that the included studies had consistent findings. However, no significant difference in hyperkalemia incidence was observed between the combination therapy and aldosterone inhibitors. The results are associated with moderate heterogeneity that indicates some variation among the studies; this may be a result of different types of aldosterone inhibitors, such as MRAs, either steroidal or non-steroidal, and aldosterone synthase inhibitors. According to the hyperkalemia, there is no significant difference in the incidence of potassium levels >5 mmol/L observed between the combination therapy and SGLT2i. However, the combination therapy was associated with a significantly lower risk of potassium levels >5 mmol/L compared to MRAs, suggesting it may be a safer option in terms of severe hyperkalemia risk. Meanwhile, no significant difference between combination therapy and either SGLT2i alone or aldosterone inhibitors alone. That indicates the combination therapy appears to be well-tolerated, with no significant increase in serious or overall adverse effects compared to monotherapy with either SGLT2i or aldosterone inhibitors.

According to our results, the combination of SGLT2i and aldosterone inhibitors has a potential synergistic effect in managing albuminuria, which is a marker of kidney damage. Our results are consistent with the results of Provenzano et al., who reported the combination of dapagliflozin (SGLT2i) and eplerenone (MRA) had a greater albuminuria-lowering effect than either drug alone in patients with CKD.^{23,29} The combination therapy also shows promise in reducing systolic blood pressure, which could have additional cardiovascular benefits. This is consistent with the results of the same trial that also found that the combination therapy resulted in a significant reduction in SBP compared to MRA alone.²⁹ While the combination therapy showed a significant reduction in eGFR compared to SGLT2 inhibitors alone, this difference was not observed when compared to aldosterone inhibitors alone. The clinical significance of this finding needs further investigation. These results are consistent with the results of Rossing et al. and Provenzano et al.^{29,30} According to hyperkalemia, the absence of a significant difference between the combination and the aldosterone inhibitors is consistent with the results of Tuttle et al. that the hyperkalemia manifested at a frequency characteristic of a chronic kidney disease cohort; however, the majority of instances did not necessitate medical intervention or the cessation of BI 690517 (a potent, highly selective aldosterone synthase inhibitor).²⁸ However, the combination has a significantly higher risk of hyperkalemia compared to the SGLT2i. Therefore, clinicians should be cautious about hyperkalemia risk when prescribing combination therapy, particularly when comparing it to SGLT2i alone. The choice between combination therapy and aldosterone inhibitors should consider individual patient risks, as combination therapy may reduce the likelihood of severe hyperkalemia. Further studies with larger sample sizes and standardized methodologies are needed to confirm these findings and clarify the clinical significance of potassium level changes.

Experimental studies and secondary analyses from large clinical outcome trials have suggested that SGLT2i and MRAs have complementary biological mechanisms of action that may result in significant reductions in albuminuria and clinically meaningful reductions in kidney outcomes. Empagliflozin and finerenone combination therapy produced a synergistic anti-albuminuric effect and enhanced survival compared with either medication alone, according to a preclinical rat trial in a model of cardio-renal illness.³² It is of great importance to determine the fundamental biological mechanisms that govern the response of each individual to treatment. To better customize therapy, future research may shed more light on the specific biological pathways and biomarkers that predict each patient's reaction to a certain medicine.

Strength points

This is the first systematic review and meta-analysis conducted to assess the safety and efficacy of SGLT2i and aldosterone inhibitors combination on patients with CKD. Our study provides promising results in the treatment of CKD and in reducing the disease progression. The included studies are low risk of bias.

Limitations

The analysis is based on only three studies, with a small sample size, which limits the generalizability of the findings. There was significant heterogeneity in some of the analyses, particularly for changes in UACR and SBP, which suggests variability in the results across studies. Additionally, different types of aldosterone inhibitors, such as MRAs and aldosterone synthase inhibitors, are a major source of heterogeneity. Therefore, more head-to-head randomized controlled trials are needed to directly compare the efficacy and safety of SGLT2i and aldosterone inhibitor combinations versus each drug separately in CKD patients. We also need more RCTs that assess the effects of the combination for longer-term durations of follow-up. The metabolic acidosis was not assessed or reported in the trials included in this review, representing a notable limitation. This omission is

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

clinically relevant, as metabolic acidosis can significantly influence potassium homeostasis by promoting extracellular potassium shifts and impairing renal potassium excretion. While the combination of SGLT2 inhibitors and MRAs was associated with a higher incidence of hyperkalemia across various MRA doses, this effect appeared to be independent of bicarbonate levels. The lack of data on acid-base status limits the ability to fully interpret the mechanisms underlying hyperkalemia in these patients. Future studies should consider evaluating metabolic acidosis and bicarbonate levels to better understand their potential contribution to electrolyte disturbances during combination therapy. While the results are promising, more research is needed to establish the long-term efficacy and safety of this combination therapy before it can be widely recommended in clinical practice.

Conclusion

The combination of SGLT2 inhibitors and aldosterone inhibitors may offer a promising approach for managing albuminuria and potentially slowing the progression of kidney disease in patients with CKD. Clinicians should be cautious about hyperkalemia risk when prescribing combination therapy. However, larger and longer-term studies are needed to confirm these findings and assess the impact on hard clinical outcomes such as progression to end-stage renal disease or cardiovascular events./

CRediT authorship contribution statement

RS and AWH: conceptualization, validation, data curation, and original draft preparation. AKA, AH, ME, and KL: methodology. RS, LM, MA, WN, GEA, and SM: writing. RS and EIB: supervision. RS, AA, and AA: writing – reviewing and editing.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Funding

This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors declare no competing interest.

Data availability

Data will be provided upon request from Reem Sayad (reem. 17289806@med.aun.edu.eg).

Acknowledgments

The authors would like to thank Dr Ahmed Elgebaly, from MedDots FZC, for his support in medical writing and editorial processing of the manuscript.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version available at https://doi.org/10.1016/j.nefro.2025. 501345.

References

- Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313:837–46.
- Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39:33–43.
- Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication – worldwide more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34:1803–5.
- 4. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7–11.
- Silvariño R, Rios P, Baldovinos G, et al. Is chronic kidney disease progression influenced by the type of renin-angiotensin-system blocker used? Nephron. 2019;143:100–7.
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63.
- Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.
- Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–94.
- Ghezzi C, Loo DD, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61:2087–97.
- Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29:190–8.
- Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–25.
- Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132:1329–39.
- Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22:39–52.
- Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present. Am J Nephrol. 2021;52:209–16.
- Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43:3781–91.
- Namsolleck P, Unger T. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant. 2014;29 Suppl_1:i62–8.
- Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69–78.
- Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152–61.
- Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50:345–56.
- Frimodt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020;29:145–51.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1–9.
- Higgins J. Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration John Wiley Sons Ltd.; 2008 .
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.
- 26. Ding H, Hu GL, Zheng XY, Chen Q, Threapleton DE, Zhou ZH. The method quality of cross-over studies involved in Cochrane Systematic Reviews. PLoS One. 2015;10: e0120519.
- McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55–61.
- 28. Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403:379–90.

A.W. Hageen, R. Sayad, A. Khaled Abdelmonem et al.

ARTICLE IN PRESS

Nefrologia xx (2025) 501345

- 29. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, Andreucci M, et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33:1569–80.
- Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodiumglucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7:36–45.
- Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int Rep. 2022;102:248–60.
- 32. Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, et al. Effects of finerenone combined with empagliflozin in a model of hypertensioninduced end-organ damage. Am J Nephrol. 2021;52:642–52.